Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting the bone marrow microenvironment in hematologic malignancies.

William S Dalton1, Lori Hazlehurst, Kenneth Shain

  • 1H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA.

Seminars in Hematology
|June 11, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Oncology Research Information Exchange Network (ORIEN) - Building a Real-World Collaborative, Patient-driven Infrastructure for Discovery Research and Precision Oncology.

Research square·2026
Same author

Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma.

Blood·2026
Same author

Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma.

Cancer research·2026
Same author

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

Bone marrow transplantation·2026
Same author

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Blood cancer journal·2026
Same author

High CTC, high-risk cytogenetics: a dangerous duo in MM?

Blood·2026
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

The tumor microenvironment can protect cancer cells from drug treatment, creating a new form of drug resistance. Targeting this extrinsic resistance may prevent acquired resistance and improve therapies for blood cancers.

Area of Science:

  • Oncology
  • Cancer Biology
  • Hematology

Background:

  • Unicellular models are limited in studying drug resistance.
  • Tumor microenvironment influences drug resistance.
  • Extrinsic factors can elicit de novo drug resistance.

Purpose of the Study:

  • Investigate the role of the tumor microenvironment in de novo drug resistance.
  • Determine if specific niches protect cancer cells from drug-induced death.
  • Explore therapeutic strategies targeting extrinsic drug resistance.

Main Methods:

  • Utilized unicellular and co-culture models.
  • Examined the bone marrow microenvironment.
  • Assessed drug-induced cell death in malignant cells.

Related Experiment Videos

Main Results:

  • Bone marrow microenvironment elements protect leukemia and myeloma cells from drug-induced death.
  • Extrinsic protection by the microenvironment represents de novo drug resistance.
  • This extrinsic resistance may precede the development of intrinsic resistance.

Conclusions:

  • The tumor microenvironment, specifically bone marrow niches, confers de novo drug resistance.
  • Targeting extrinsic resistance mechanisms is crucial for overcoming acquired resistance.
  • Interventions focused on the tumor microenvironment could enhance drug therapy for hematologic malignancies.